Post Profile

Use Of Genetic Information May Help Predict Likelihood Of Survival Following Chemotherapy For Breast Cancer

Development of a predictive test that included genomic signatures that indicated chemoresistance, chemosensitivity and endocrine sensitivity for women with newly diagnosed breast cancer identified patients with a high probability of survival following chemotherapy, according to a study in the May 11 issue of JAMA. Identification of patients with high likelihood of survival following a standard chemotherapy regimen (and then endocrine therapy, if estrogen receptor [ER]-positive) would reaffirm a treatment decision regarding the use of chemotherapy.
read more

See more about: Breast Cancer

Related Posts:

1 Step Closer To Personalized Medicine: Stroma Genomic Signature Predicts Resistance To Anthracyclin-Based Chemotherapy In Breast Cancer

Health : Medical News Today (6 years ago)

Researchers at the Swiss Institute of Bioinformatics and the Swiss National Center of Competence in Research in Molecular Oncology in Lausanne have developed a new test to predict how breast cancer patients respond to chemotherapy, ... Read Post

Gene Signature Identifies Breast Cancer Patients Who Will Respond To Chemotherapy

Health : Medical News Today (6 years ago)

Researchers have identified a genetic signature that can predict which breast cancer patients will respond well to treatment with epirubicin, a widely used form of chemotherapy. Although among the most effective chemotherapies in br... Read Post

Genomic Test Shows Promise As Predictor Of Chemotherapy Response, Survival For Women With Invasive Breast Cancer

Health : Medical News Today (4 years ago)

A new genomic test combining multiple signatures a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity shows promise as a predictor of chemotherapy response and survival benefit in... Read Post


Copyright © 2015 Regator, LLC